Nebivolol Ratiopharm (Nebivolol Hydrochloride)

Nebivolol works as a selective β1‑adrenergic receptor antagonist, which slows the heart’s response to sympathetic stimulation. It also enhances endothelial nitric oxide production, leading to relaxation of blood vessels and a further reduction in blood pressure.

The appropriate dose of Nebivolol Ratiopharm is determined by the prescribing healthcare professional based on the patient’s clinical condition, blood pressure response, and any concomitant therapies. Dosage adjustments are made according to individual therapeutic needs.

Safety data for nebivolol in pregnancy and lactation are limited. It is generally recommended to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare provider is essential.

To order Nebivolol Ratiopharm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

Nebivolol offers a dual mechanism of β1‑blockade and nitric‑oxide‑mediated vasodilation, which can provide better heart‑rate control and improved vascular tone compared with traditional β‑blockers. Unlike some ACE inhibitors or calcium‑channel blockers, it may have a more favorable metabolic profile in certain patients.

Nebivolol Ratiopharm tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain its stability and potency.

Nebivolol Ratiopharm is taken orally, usually once daily, with or without food as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include severe bradycardia, symptomatic hypotension, heart block, and bronchospasm, especially in patients with pre‑existing cardiac conduction disorders or reactive airway disease. Prompt medical attention is required if any of these events occur.

Nebivolol Ratiopharm should be avoided in patients with known hypersensitivity to nebivolol or any excipients, severe bradycardia, second‑ or third‑degree atrioventricular block, uncompensated heart failure, or uncontrolled asthma/COPD without careful medical supervision.